Business
FDA Fast-Tracks Vyvgart Expansion, Spotlighting Argenx's Pipeline and Market Potential
The FDA's Priority Review for Vyvgart's label expansion in myasthenia gravis accelerates Argenx's growth strategy, while investors weigh the company's broader pipeline against its current valuation.